BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bayoumy AB, Simsek M, Seinen ML, Mulder CJJ, Ansari A, Peters GJ, De Boer NK. The continuous rediscovery and the benefit-risk ratio of thioguanine, a comprehensive review. Expert Opin Drug Metab Toxicol 2020;16:111-23. [PMID: 32090622 DOI: 10.1080/17425255.2020.1719996] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Gerussi A, Rigamonti C, Elia C, Cazzagon N, Floreani A, Pozzi R, Pozzoni P, Claar E, Pasulo L, Fagiuoli S, Cristoferi L, Carbone M, Invernizzi P. Coronavirus Disease 2019 (COVID-19) in autoimmune hepatitis: a lesson from immunosuppressed patients. Hepatol Commun. 2020;. [PMID: 32838102 DOI: 10.1002/hep4.1557] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 11.0] [Reference Citation Analysis]
2 Lv Z, Cano KE, Jia L, Drag M, Huang TT, Olsen SK. Targeting SARS-CoV-2 Proteases for COVID-19 Antiviral Development. Front Chem 2022;9:819165. [DOI: 10.3389/fchem.2021.819165] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
3 Swaim CD, Dwivedi V, Perng YC, Zhao X, Canadeo LA, Harastani HH, Darling TL, Boon ACM, Lenschow DJ, Kulkarni V, Huibregtse JM. 6-Thioguanine blocks SARS-CoV-2 replication by inhibition of PLpro. iScience 2021;24:103213. [PMID: 34632326 DOI: 10.1016/j.isci.2021.103213] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Bayoumy AB, de Boer NKH, Ansari AR, Crouwel F, Mulder CJJ. Unrealized potential of drug repositioning in europe during COVID-19 and beyond: a physcian's perspective. J Pharm Policy Pract 2020;13:45. [PMID: 32695427 DOI: 10.1186/s40545-020-00249-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
5 Gao X, Qin B, Chen P, Zhu K, Hou P, Wojdyla JA, Wang M, Cui S. Crystal structure of SARS-CoV-2 papain-like protease. Acta Pharm Sin B 2021;11:237-45. [PMID: 32895623 DOI: 10.1016/j.apsb.2020.08.014] [Cited by in Crossref: 102] [Cited by in F6Publishing: 75] [Article Influence: 102.0] [Reference Citation Analysis]
6 Swaim CD, Perng YC, Zhao X, Canadeo LA, Harastani HH, Darling TL, Boon ACM, Lenschow DJ, Huibregtse JM. 6-Thioguanine blocks SARS-CoV-2 replication by inhibition of PLpro protease activities. bioRxiv 2020:2020. [PMID: 32637945 DOI: 10.1101/2020.07.01.183020] [Cited by in Crossref: 12] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]
7 Bayoumy AB, Mulder CJJ, Loganayagam A, Sanderson JD, Anderson S, Boekema PJ, Derijks LJJ, Ansari AR. Relationship Between Thiopurine S-Methyltransferase Genotype/Phenotype and 6-Thioguanine Nucleotide Levels in 316 Patients With Inflammatory Bowel Disease on 6-Thioguanine. Ther Drug Monit 2021;43:617-23. [PMID: 34521801 DOI: 10.1097/FTD.0000000000000869] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Bayoumy AB, van Liere ELSA, Simsek M, Warner B, Loganayagam A, Sanderson JD, Anderson S, Nolan J, de Boer NK, Mulder CJJ, Ansari A. Efficacy, safety and drug survival of thioguanine as maintenance treatment for inflammatory bowel disease: a retrospective multi-centre study in the United Kingdom. BMC Gastroenterol 2020;20:296. [PMID: 32917155 DOI: 10.1186/s12876-020-01441-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
9 Terziroli Beretta-Piccoli B, Mieli-Vergani G, Vergani D. Autoimmmune hepatitis. Cell Mol Immunol 2021. [PMID: 34580437 DOI: 10.1038/s41423-021-00768-8] [Reference Citation Analysis]
10 Biemans VBC, Savelkoul E, Gabriëls RY, Simsek M, Dijkstra G, Pierik MJ, West RL, de Boer NKH, Hoentjen F. A comparative analysis of tioguanine versus low-dose thiopurines combined with allopurinol in inflammatory bowel disease patients. Aliment Pharmacol Ther 2020;51:1076-86. [PMID: 32339331 DOI: 10.1111/apt.15730] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
11 Nieciecka D, Rękorajska A, Cichy D, Końska P, Żuk M, Krysiński P. Synthesis and Characterization of Magnetic Drug Carriers Modified with Tb3+ Ions. Nanomaterials 2022;12:795. [DOI: 10.3390/nano12050795] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
12 Jiang H, Yang P, Zhang J. Potential Inhibitors Targeting Papain-Like Protease of SARS-CoV-2: Two Birds With One Stone. Front Chem 2022;10:822785. [DOI: 10.3389/fchem.2022.822785] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Cotta Filho CK, Oliveira-paula GH, Rondon Pereira VC, Lacchini R. Clinically relevant endothelial nitric oxide synthase polymorphisms and their impact on drug response. Expert Opinion on Drug Metabolism & Toxicology 2020;16:927-51. [DOI: 10.1080/17425255.2020.1804857] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]